Rexulti (Brexpiprazole) Dosing for Schizophrenia
For adults with schizophrenia, start Rexulti at 1 mg once daily for days 1-4, increase to 2 mg daily on days 5-7, then titrate to the target dose of 2-4 mg daily on day 8 based on response and tolerability, with a maximum of 4 mg daily. 1
Adult Dosing Algorithm
Initial titration schedule:
- Days 1-4: 1 mg once daily
- Days 5-7: 2 mg once daily
- Day 8 onward: Increase to target dose of 2-4 mg once daily based on clinical response and tolerability
- Maximum dose: 4 mg once daily
The medication can be taken with or without food 1.
Adolescent Dosing (Ages 13-17)
For adolescents, use a slower titration:
- Days 1-4: 0.5 mg once daily
- Days 5-7: 1 mg once daily
- Day 8: 2 mg once daily
- Subsequent weeks: Can increase by 1 mg increments weekly
- Target dose: 2-4 mg once daily
- Maximum dose: 4 mg once daily 1
The FDA approved this adolescent dosing based on pharmacokinetic modeling showing comparable drug exposure between adults and adolescents at these doses 2.
Dose Adjustments for Special Populations
Hepatic impairment (Child-Pugh score ≥7):
- Maximum dose: 3 mg daily 1
Renal impairment (CrCl <60 mL/min):
- Maximum dose: 3 mg daily 1
CYP2D6 poor metabolizers:
- Use half the recommended dose 1
Concomitant strong CYP3A4 or CYP2D6 inhibitors:
- Use half the recommended dose
- If patient is a CYP2D6 poor metabolizer taking strong/moderate CYP3A4 inhibitors: use one quarter of the recommended dose 1
Concomitant strong CYP3A4 inducers:
- Double the usual dose over 1-2 weeks
- When inducer is discontinued, reduce back to original dose over 1-2 weeks 1
Clinical Context and Evidence Quality
The FDA labeling 1 provides the most authoritative dosing guidance and should be followed precisely. Clinical trials demonstrated that the 2-4 mg daily range achieved a number needed to treat (NNT) of 7 for acute response and NNT of 4 for relapse prevention 3, 4.
Common pitfalls to avoid:
- Akathisia is the most common adverse effect (5.5% vs 4.6% placebo in schizophrenia trials), though the risk is relatively low (NNH = 112) 3, 4
- Weight gain occurs in approximately 10% of patients (≥7% increase from baseline) with short-term use, but may be more pronounced with long-term treatment 3
- Do not rush titration—the gradual dose escalation helps minimize side effects while achieving therapeutic levels
Recent expert consensus from Japan 5 and international guidelines 6 support brexpiprazole as a first-line option, particularly for patients requiring a favorable side-effect profile regarding extrapyramidal symptoms and metabolic effects. The 2025 INTEGRATE guidelines 6 recommend considering brexpiprazole as a D2 partial agonist option, with switching to agents like risperidone, paliperidone, or olanzapine if inadequate response occurs after 4 weeks at therapeutic doses.
Monitoring priorities: